Get started
Author

Soraya Diez-Posada

Observed name: S. Diez-Posada
ORCID: 0009-0006-8892-556X
Observed ORCID: 0009-0006-8892-556X
OpenAlex ID: A5087428912
Small-Format Drug Conjugates: A Viable Alternative to ADCs for Solid Tumours?
2018 · Mahendra Deonarain, Gokhan Yahioglu, et al. · Antibodies · 94
PDF
Development of a novel recombinant biotherapeutic with applications in targeted therapy of human arthritis
2011 · Panagiotis Kamperidis, Tahereh Kamalati, et al. · Arthritis & Rheumatism · 13
Anti-HER2, High-DAR Antibody Fragment–Drug Conjugates with a Glucuronide-Based MMAE Linker–Payload Demonstrate Superior Efficacy over IgG-Based ADCs
2025 · Ioanna Stamati, Gokhan Yahioglu, et al. · Molecular Cancer Therapeutics · 5
Abstract 909: Antibody fragment drug-conjugates (FDCs)-application of ANT-043 and ANT-045 in solid tumors
2021 · Mahendra P. Deonarain, Gokhan Yahioglu, et al. · Cancer Research · 3
Abstract 2901: Gastric cancer antibody fragment drug-conjugates (FDCs): From concept to clinical development
2020 · Mahendra P. Deonarain, Gokhan Yahioglu, et al. · Cancer Research · 2
Abstract 4399: ANT045: A novel format, antibody fragment drug-conjugate (FDC) product for challenging cMET-expressing solid tumors
2026 · Mahendra Deonarain, Bryan Edwards, et al. · Cancer Research
Abstract 2408: ADCs in cancer treatment: SPR-driven insights into discovery and characterization.
2026 · Soraya Diez-Posada, Cynthia Shuman, et al. · Cancer Research
Supplementary Figure 4 from Anti-HER2, High-DAR Antibody Fragment–Drug Conjugates with a Glucuronide-Based MMAE Linker–Payload Demonstrate Superior Efficacy over IgG-Based ADCs
2025 · Ioanna Stamati, Gokhan Yahioglu, et al.
PDF
Supplementary Data from Anti-HER2, High-DAR Antibody Fragment–Drug Conjugates with a Glucuronide-Based MMAE Linker–Payload Demonstrate Superior Efficacy over IgG-Based ADCs
2025 · Ioanna Stamati, Gokhan Yahioglu, et al.
Supplementary Figure 1 from Anti-HER2, High-DAR Antibody Fragment–Drug Conjugates with a Glucuronide-Based MMAE Linker–Payload Demonstrate Superior Efficacy over IgG-Based ADCs
2025 · Ioanna Stamati, Gokhan Yahioglu, et al.
PDF
Supplementary Figure 9 from Anti-HER2, High-DAR Antibody Fragment–Drug Conjugates with a Glucuronide-Based MMAE Linker–Payload Demonstrate Superior Efficacy over IgG-Based ADCs
2025 · Ioanna Stamati, Gokhan Yahioglu, et al.
PDF
Supplementary Table 2 from Anti-HER2, High-DAR Antibody Fragment–Drug Conjugates with a Glucuronide-Based MMAE Linker–Payload Demonstrate Superior Efficacy over IgG-Based ADCs
2025 · Ioanna Stamati, Gokhan Yahioglu, et al.
Supplementary Table 4 from Anti-HER2, High-DAR Antibody Fragment–Drug Conjugates with a Glucuronide-Based MMAE Linker–Payload Demonstrate Superior Efficacy over IgG-Based ADCs
2025 · Ioanna Stamati, Gokhan Yahioglu, et al.
Supplementary Table 1 from Anti-HER2, High-DAR Antibody Fragment–Drug Conjugates with a Glucuronide-Based MMAE Linker–Payload Demonstrate Superior Efficacy over IgG-Based ADCs
2025 · Ioanna Stamati, Gokhan Yahioglu, et al.
Supplementary Figure 2 from Anti-HER2, High-DAR Antibody Fragment–Drug Conjugates with a Glucuronide-Based MMAE Linker–Payload Demonstrate Superior Efficacy over IgG-Based ADCs
2025 · Ioanna Stamati, Gokhan Yahioglu, et al.
Supplementary Figure 3 from Anti-HER2, High-DAR Antibody Fragment–Drug Conjugates with a Glucuronide-Based MMAE Linker–Payload Demonstrate Superior Efficacy over IgG-Based ADCs
2025 · Ioanna Stamati, Gokhan Yahioglu, et al.
PDF
Supplementary Figure 7 from Anti-HER2, High-DAR Antibody Fragment–Drug Conjugates with a Glucuronide-Based MMAE Linker–Payload Demonstrate Superior Efficacy over IgG-Based ADCs
2025 · Ioanna Stamati, Gokhan Yahioglu, et al.
PDF
Supplementary Figure 5 from Anti-HER2, High-DAR Antibody Fragment–Drug Conjugates with a Glucuronide-Based MMAE Linker–Payload Demonstrate Superior Efficacy over IgG-Based ADCs
2025 · Ioanna Stamati, Gokhan Yahioglu, et al.
PDF
Supplementary Figure 10 from Anti-HER2, High-DAR Antibody Fragment–Drug Conjugates with a Glucuronide-Based MMAE Linker–Payload Demonstrate Superior Efficacy over IgG-Based ADCs
2025 · Ioanna Stamati, Gokhan Yahioglu, et al.
PDF
Supplementary Table 3 from Anti-HER2, High-DAR Antibody Fragment–Drug Conjugates with a Glucuronide-Based MMAE Linker–Payload Demonstrate Superior Efficacy over IgG-Based ADCs
2025 · Ioanna Stamati, Gokhan Yahioglu, et al.
Supplementary Figure 8 from Anti-HER2, High-DAR Antibody Fragment–Drug Conjugates with a Glucuronide-Based MMAE Linker–Payload Demonstrate Superior Efficacy over IgG-Based ADCs
2025 · Ioanna Stamati, Gokhan Yahioglu, et al.
PDF
Supplementary Figure 6 from Anti-HER2, High-DAR Antibody Fragment–Drug Conjugates with a Glucuronide-Based MMAE Linker–Payload Demonstrate Superior Efficacy over IgG-Based ADCs
2025 · Ioanna Stamati, Gokhan Yahioglu, et al.
PDF
Supplementary Table 5 from Anti-HER2, High-DAR Antibody Fragment–Drug Conjugates with a Glucuronide-Based MMAE Linker–Payload Demonstrate Superior Efficacy over IgG-Based ADCs
2025 · Ioanna Stamati, Gokhan Yahioglu, et al.
Data from Anti-HER2, High-DAR Antibody Fragment–Drug Conjugates with a Glucuronide-Based MMAE Linker–Payload Demonstrate Superior Efficacy over IgG-Based ADCs
2025 · Ioanna Stamati, Gokhan Yahioglu, et al.
13 (PB001): ANT-045: Demonstrating the promise of better penetrating, safer Antibody Fragment Drug-Conjugates
2024 · M. Deonarain, G. Yahioglu, et al. · European Journal of Cancer
Works count: 28
Citation count: 117
H-index: 3
I10-index: 2
Year
Topic
Type